Cyclerion Therapeutics, Inc.
CYCNHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cyclerion Therapeutics, Inc. focuses on Biotechnology services and products. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system. The $19.9M market capitalization puts CYCN squarely in micro-cap range for its industry. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease.
Market Cap
$19.9M
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
-3.24
EPS (TTM)
$-1.68
EPS (Fwd)
$-1.31
ROE
-98.2%
ROA
-52.3%
Cash
$1.4M
Total Debt
$0
Free CF
-$2.1M
52W Change
63.5%
Annual Financials
Cash vs Debt
Where CYCN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CYCN finished 58.04% above its 150-day moving average ($2.86) and 79.37% above its 200-day moving average ($2.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CYCN overbought or oversold?
At the September 3, 2026 close, CYCN's RSI(14) was 63.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cyclerion Therapeutics, Inc. reports $1.4M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$2.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -98.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $297K (2022) to $2.1M (2025), reflecting a 598% increase over the period.
With a beta above 1.5, CYCN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CYCN.